QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

HCM

QT50HUTCHMED (China) Limited
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Hong Kong
Latest market price
10.28
+0.16+1.58%
OverviewShort InterestFilings
HCMQT50HUTCHMED (China) Limited·NASDAQ
OverviewShort InterestFilings
10.28+1.58%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96TEVA-3.32%$31.48VTRS-2.29%$15.37ELAN+3.55%$24.22RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86
Snapshot
Index-P/E46.21EPS (ttm)
2.69
Insider Own-
Shs Outstand-
Perf Week-3.75%
Market Cap1.80BForward P/E26.52EPS next Y0.39Insider Trans-Shs Float-Perf Month-14.76%
Enterprise Value1.83BPEG0.04EPS next Q-Inst Own-Short Float-Perf Quarter-25.62%
Income38.91MP/S3.28EPS this Y-90.49%Inst Trans-Short Ratio-Perf Half Y-22.06%
Sales548.51MP/B17.06EPS next Y51.53%ROA26.06%Short Interest-Perf YTD-22.88%
Book/sh-P/C-EPS next 5Y46.24%ROE37.04%52W High19.50 -47.28%Perf Year-34.56%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-2.35%52W Low10.01 2.70%Perf 3Y-
Dividend Est.-EV/EBITDA-70.71Sales past 3/5Y8.89% 19.26%Gross Margin11.64%Volatility2.06% 2.25%Perf 5Y-
Dividend TTM-EV/Sales3.33EPS Y/Y TTM-Oper. Margin-7.14%ATR (14)0.36Perf 10Y-
Dividend Ex-Date-Quick Ratio4.83Sales Y/Y TTM-4.44%Profit Margin83.30%RSI (14)28.47Recom2.30
Dividend Gr. 3/5Y-Current Ratio4.96EPS Q/Q-SMA20-7.45%Beta0.64Target Price13.60
Payout0.00%Debt/Eq0.08Sales Q/Q-9.15%SMA50-19.09%Rel Volume1.13Prev Close10.12
Employees1,811LT Debt/Eq0.06Earnings-SMA200-28.24%Avg Volume44.38KPrice10.28
IPO DateMar 16, 2016Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA-1.03Volume50,336Change1.58%
Analyst Ratings
DateActionAnalystRatingTarget
May-28-26ReiteratedMorgan StanleyUnderweight$18 → $14
Sep-22-25DowngradeMorgan StanleyEqual Weight → Underweight
May-14-24ReiteratedMorgan Stanley$18
Nov-24-23UpgradeDeutsche BankHold → Buy
Sep-22-21DowngradeGoldman SachsBuy → Neutral
Latest News
Jun-12-26
Jun-12-2603:03AM
Reported Earlier, HUTCHMED Says Sovleplenib Shows Favorable Safety Profile With Fewer Grade 3 Adverse Events Than PlaceboBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue602550630
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A548337349
Gross Profit54213281
Selling, General and Administrative Excl. Other98103113
Research and Development190164213
Other Operating Expense-2140-4
Operating Income-20-55-44
Interest Expense033
Unusual Expense
———
Non-Operating Income (Expense)000
Net Income Before Taxes53452345
Income Taxes68647
Consolidated Net Income46645838
Net Income From Continuing Operations46845938
Net Income46645838
EPS (Recurring)2.772.650.22
EPS (Basic, Before Extraordinaries)2.772.650.22
EPS (Diluted)2.692.600.22
EBITDA-8-41-31
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio3.825.13—
Price To Sales Ratio2.994.17—
Gross Margin8.9738.7344.60
Operating Margin-3.32-10.00-6.98
Net Margin77.4183.276.03
Shares Outstanding175172171
Market Capitalization1,7992,293—
Operating Lease Expense
———
Insider Trading Volume
$11.06$9.37$7.67$5.97$4.28● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR